LXXGF - LexaGene Holdings Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.5165
-0.0063 (-1.21%)
At close: 3:50PM EDT
Stock chart is not supported by your current browser
Previous Close0.5228
Open0.6000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4929 - 0.6000
52 Week Range0.3500 - 1.0200
Volume41,015
Avg. Volume57,486
Market Cap36.942M
Beta (3Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-0.1190
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    LexaGene Completes Development of Antibiotic Resistance Panel

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today that it has completed the development of an antibiotic resistance marker panel comprised of 12 assays targeting antibiotic resistance genes commonly found in bacterial pathogens. This further expands the Company’s capabilities in providing a complete testing solution for veterinarians to rapidly determine the cause of an infection and whether any antibiotic resistance factors are present.  This information can then be used to prescribe the most effective therapy.

  • GlobeNewswire19 days ago

    LexaGene’s Technology Successfully Detects a Common Fungus That Damages Agricultural Crops

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that its LX analyzer successfully detects Botrytis cinerea, also known as Gray Mold, which is a common agricultural pathogen responsible for $10 to $100 billion in agricultural losses worldwide each year.***  This fungus infects over 200 plant species causing the most yield loss in strawberries, grapes and cannabis.

  • ACCESSWIRE25 days ago

    Uptick Newswire Hosts LexaGene Holdings Inc. on The Stock Day Podcast to Discuss the Beta Launch of Their Pathogen Detection Device

    PHOENIX, AZ / ACCESSWIRE / April 24, 2019 / Uptick Newswire Stock Day Podcast welcomed LexaGene (LXXGF) (LXG.V) (''the Company''), a biotechnology company developing the very first fully automated pathogen detection platform that is open-access. President, Daryl Rebeck, joined Stock Day host Everett Jolly.

  • GlobeNewswire25 days ago

    LexaGene’s Technology Identifies Genetic Mutations Directly from Cheek Swabs

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that its LX technology can successfully detect single-point gene mutations from cheek swabs.

  • GlobeNewswirelast month

    LexaGene Engages Bristol Capital LTD. to Provide Investor Relations and Communications Services

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has entered into a consulting agreement with Bristol Capital LTD. ("Bristol"), a leading investor relations and capital markets advisory firm servicing Canadian and US microcap and small cap companies across international markets, to provide investor relations and communication services. Bristol will provide investor relations services to LexaGene, including the development of new and improved investor materials, introductions to Bristol’s direct network of investment professionals, coordination of public events and proactive investor relations campaigns to increase LexaGene’s exposure in the investment community.

  • GlobeNewswire2 months ago

    Former Head of Food Safety at Chipotle Mexican Grills Joins LexaGene’s Scientific Advisory Board

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, is pleased to announce that food safety innovator Dr. James Marsden has joined LexaGene’s Scientific Advisory Board (SAB) to steer LexaGene’s penetration into the food industry.

  • GlobeNewswire2 months ago

    LexaGene’s Closes Oversubscribed Private Placement

    The Company has issued 4,375,271 units (the “Units”) at a price of $0.65 CAD per Unit.  Each Unit is comprised of one common share and one warrant, with each whole warrant entitling the holder to purchase one common share of the Company for a period of up to fifteen months at a price of $0.85 CAD. The warrants are subject to an accelerated expiry in circumstances where, at any time commencing two (2) months from the date the warrants are issued, if for the preceding five (5) consecutive trading days, the daily volume weighted average trading price of the Company’s common shares is greater than $1.10 CAD, in which case the Company may accelerate the expiry date of the warrants by giving notice to the holders thereof and in such case the warrants will expire on the 30th calendar day after the date of such notice.

  • GlobeNewswire2 months ago

    LexaGene Announces C$1.95 Million Private Placement

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that, subject to acceptance by the Exchange, it intends to complete a non-brokered private placement of up to 3,000,000 units of LexaGene (the “Units”) at an issue price of CDN $0.65 per Unit, for gross proceeds of up to CDN $1,950,000 (the “Private Placement”). Each Unit is comprised of one common share in the capital of LexaGene (the “LexaGene Shares”) and one common share purchase warrant (each a “Warrant”).

  • GlobeNewswire2 months ago

    LexaGene’s CEO Invited by USDA to Present a Seminar on the Benefits of Adopting Rapid Genetic Testing to Improve Food Safety

    BEVERLY, Mass., March 11, 2019 -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen.

  • GlobeNewswire2 months ago

    LexaGene’s LX Technology Successfully Detects Pathogenic E. coli O157:H7 Bacteria from Romaine Lettuce Wash

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that their LX technology successfully detected E. coli O157:H7 in a blinded study focused on romaine lettuce wash. Dr. Jack Regan, LexaGene’s CEO and Founder, adds, “Our genetics-based technology is extremely sensitive and will return results in ~ 1 hour.

  • GlobeNewswire3 months ago

    LexaGene Completes Pilot Clinical Study and Reports Results

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that as part of the Company’s previously announced pilot clinical study, the LX genetic analyzer technology, in a fully automated manner, successfully detected all six of the known pathogens in 107 canine urine samples tested. Previously, the Company announced that the LX technology successfully detected dual infections and pathogens harboring antibiotic resistance factors.

  • GlobeNewswire3 months ago

    LexaGene’s Technology Successfully Detects Antibiotic Resistance Factors

    BEVERLY, Mass., Feb. 12, 2019 -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen.

  • GlobeNewswire3 months ago

    LexaGene’s Technology Successfully Detects Dual Infected Samples

    BEVERLY, Mass., Feb. 07, 2019 -- LexaGene Holdings Inc. (OTCQB: LXXGF; TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen.

  • GlobeNewswire3 months ago

    LexaGene Starts Clinical Study Using its Technology

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that it has started a clinical study to collect data using its LX genetic analyzer technology. LexaGene is using frozen samples that were collected from dogs suspected of having a UTI.  These frozen samples are being provided by Ethos Veterinary Health Group. LexaGene’s scientists are loading thawed samples on to the Company’s automated genetic analyzer for testing.  Prior to sending the samples to LexaGene, Ethos shipped duplicate samples to their standard reference laboratory for testing so that LexaGene can compare their generated data to the current method.

  • GlobeNewswire4 months ago

    LexaGene Announces Formation of Scientific Advisory Board

    TSX-V: LXG) (the “Company”), a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers, announced today that the Company has formed a scientific advisory board (SAB) to assist the Company in product positioning and its go-to-market strategy.  The SAB is comprised of key opinion leaders in the Company’s targeted markets, namely food safety, veterinary diagnostics, and open-access markets such as biodefense.  The initial SAB members include Dr. Kimothy Smith DVM PhD and Mr. Shawn Stevens JD.  Other SAB members will be added over the coming months to complete a five-member advisory board.

  • GlobeNewswire4 months ago

    LexaGene Featured on ABC Affiliate WCVB-TV Boston

    TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation and assays for pathogen detection, today announced that the Company was featured on ABC-affiliated television station WCVB Boston on a segment of ‘Cutting Edge’ on December 21, 2018. “We were very honored to be featured in ABC’s ‘Cutting Edge’ Program and to have the opportunity to showcase LexaGene’s vision and the impact this technology can have on the world. To help solve this problem, LexaGene is developing a low-cost – yet extremely sensitive – pathogen detection instrument that will provide food safety officers at food processing and packaging facilities with a more rapid assessment on the safety of their products,” states Dr. Jack Regan, LexaGene’s CEO and Founder.

  • GlobeNewswire5 months ago

    LexaGene Completes Development of Canine UTI Syndromic Panel

    TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation and assays for pathogen detection, today announced the completion of a syndromic panel to detect urinary tract infection (UTI) in small animals. The assay is capable of detecting each of the eight most common pathogens responsible for the majority (95%) of all clinical canine UTI cases.  LexaGene's UTI panel is designed to detect the causative pathogens with greater sensitivity and specificity than traditional culture-based detection which is prone to false positive results. Currently, in the US alone, there are 90 million dogs, with an estimated 5.4 million tests performed for urinary tract infections.  These infections can be caused by at least 69 different pathogens, but 95% of these infections are caused by just 8 pathogens.

  • GlobeNewswire5 months ago

    LexaGene Attends Industry Engagement Meeting with the Department of Homeland Security

    DHS was founded in response to the September 11th attacks and the bioterrorist attacks on September 18th in 2001 when anonymous letters laced with deadly anthrax spores were delivered to media companies and congressional offices resulting in five deaths and 17 others being infected.  Since these events, DHS has supported and implemented proven technologies into their BioWatch Program to better detect bioterrorist attacks. Dr. Jack Regan, LexaGene’s CEO and Founder, previously worked at Lawrence Livermore National Laboratory developing a DHS-funded Autonomous Pathogen Detection System (APDS).  This system was designed to automatically screen the air for weaponized bacteria.  After its completion, the APDS system was validated by DHS and became an active component of their BioWatch Program, where it operated 24/7 providing autonomous surveillance.  Despite the successes of the system, Dr. Regan’s experience developing this technology motivated him to design a next-generation genetic analyzer that would be more powerful than the APDS system and have uses beyond those of biodefense.  The results of these efforts are now being realized through LexaGene’s development of the LX2™ Genetic Analyzer.

  • GlobeNewswire6 months ago

    LexaGene Named One of the 10 Most Promising Food Solution Providers

    TSX-V: LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced that following the most recent widespread multi-state recall of romaine lettuce contaminated with E.coli, and a food safety alert from the Centers for Disease Control (CDC) declaring all romaine lettuce unsafe to eat, LexaGene has been voted among the “10 Most Promising Food and Beverages Solution Providers 2018” by CIOReview based on the Company’s pathogen detection system, the LX2™ Genetic Analyzer.

  • CNW Group10 months ago

    LexaGene Holdings Inc. Completes $5.75 Million Bought Deal Financing Underwriters Exercise Over-Allotment Option in Full

    VANCOUVER , July 11, 2018 /CNW/ - LexaGene Holdings Inc. (TSX VENTURE: LXG) (OTCQB: LXXGF) ("LexaGene" or the "Company") has closed its previously announced bought deal offering of units (the "Offering") for aggregate gross proceeds of $5.75 million .  In connection with this closing the underwriters exercised the over-allotment option in full.  As a result, the Company issued 5,750,000 units at a price of $1.00 per unit, each unit consisting of one common share and one –half of one common share purchase warrant.  Each whole warrant entitles the holder to purchase, subject to adjustment in certain circumstances, one additional common share at a price of $1.30 per common share until July 11, 2021 . The financing was led by Canaccord Genuity Corp. and included Echelon Wealth Partners Inc.  The Company issued to the underwriters an aggregate of 402,500 compensation warrants, each compensation warrant entitling the holder to purchase one common share of the Company at a price of $1.00 per share until July 11, 2021 .